Activation of the transcription factor FosB/activating protein-1 (AP-1) is a prominent downstream signal of the extracellular nucleotide receptor P2RX7 in monocytic and osteoblastic cells.
Activation of the ionotropic P2RX7 nucleotide receptor by extracellular ATP has been implicated in modulating inflammatory disease progression. Continuous exposure of P2RX7 to ligand can result in apoptosis in many cell types, including monocytic cells, whereas transient activation of P2RX7 is linked to inflammatory mediator production and the promotion of cell growth. Given the rapid hydrolysis of ATP in the circulation and interstitial space, transient activation of P2RX7 appears critically important for its action, yet its effects on gene expression are unclear. The present study demonstrates that short-term stimulation of human and mouse monocytic cells as well as mouse osteoblasts with P2RX7 agonists substantially induces the expression of several activating protein-1 (AP-1) members, particularly FosB. The potent activation of FosB after P2RX7 stimulation is especially noteworthy considering that little is known concerning the role of FosB in immunological regulation. Interestingly, the magnitude of FosB activation induced by P2RX7 stimulation appears greater than that observed with other known inducers of FosB expression. In addition, we have identified a previously unrecognized role for FosB in osteoblasts with respect to nucleotide-induced expression of cyclooxygenase-2 (COX-2), which is the rate-limiting enzyme in prostaglandin biosynthesis from arachidonic acid and is critical for osteoblastic differentiation and immune behavior. The present studies are the first to link P2RX7 action to FosB/AP-1 regulation in multiple cell types, including a role in nucleotide-induced COX-2 expression, and support a role for FosB in the control of immune and osteogenic function by P2RX7.
Gavala
Monica L
ML
Department of Biomolecular Chemistry, University of Wisconsin School of Medicine, Madison, Wisconsin 53706, USA.
Hill
Lindsay M
LM
Lenertz
Lisa Y
LY
Karta
Maya R
MR
Bertics
Paul J
PJ
D000818:Animals; D002460:Cell Line; D002470:Cell Survival; D051546:Cyclooxygenase 2 / Q000378:metabolism; D006801:Humans; D007107:Immune System; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D008954:Models, Biological; D009000:Monocytes / Q000378:metabolism*; D010006:Osteoblasts / Q000378:metabolism*; D018048:Receptors, Purinergic P2 / Q000737:chemistry*; D058486:Receptors, Purinergic P2X7; D015398:Signal Transduction; D018808:Transcription Factor AP-1 / Q000378:metabolism*
C546468:P2RX7 protein, human; C546469:P2rx7 protein, mouse; D018048:Receptors, Purinergic P2; D058486:Receptors, Purinergic P2X7; D018808:Transcription Factor AP-1; D051546:Cyclooxygenase 2
Cell. 1991 Feb 22;64(4):751-9
1900040
J Allergy Clin Immunol. 2008 Jan;121(1):215-221.e1
18028998
Free Radic Biol Med. 2007 May 15;42(10):1506-16
17448897
J Biol Chem. 2003 Jan 17;278(3):1549-60
12424250
Purinergic Signal. 2007 Mar;3(1-2):39-51
18404417
Arch Biochem Biophys. 1999 Feb 15;362(2):197-202
9989927
J Cell Biochem. 2003 Jan 1;88(1):104-12
12461779
Pharmacol Rev. 2006 Mar;58(1):58-86
16507883
Neuropharmacology. 1997 Sep;36(9):1127-39
9364468
J Biol Chem. 2004 Nov 26;279(48):49795-803
15383527
J Leukoc Biol. 2008 Oct;84(4):1159-71
18625910
J Bone Miner Metab. 2005;23 Suppl:84-9
15984421
Am J Pathol. 2002 Jul;161(1):275-82
12107112
J Biol Chem. 2005 Dec 30;280(52):42952-9
16269410
J Immunol. 1991 Mar 1;146(5):1626-32
1847168
J Leukoc Biol. 1999 Nov;66(5):723-6
10577500
Nat Rev Immunol. 2007 Apr;7(4):292-304
17380158
J Leukoc Biol. 1998 Aug;64(2):265-73
9715267
J Biol Chem. 2000 Sep 1;275(35):26792-8
10854431
Mol Endocrinol. 2003 Jul;17(7):1356-67
12677010
J Biol Chem. 1999 May 14;274(20):14315-24
10318853
J Leukoc Biol. 2004 Jun;75(6):1173-82
15075366
Mol Pharmacol. 2003 Oct;64(4):785-95
14500734
Cell Death Differ. 1998 Mar;5(3):191-9
10200464
J Clin Invest. 2002 Sep;110(5):651-8
12208866
J Neuroimmunol. 2005 Sep;166(1-2):113-25
15979729
J Biol Chem. 2001 Jan 5;276(1):125-32
11016935
J Immunol. 2003 Aug 1;171(3):1304-11
12874219
J Biol Chem. 2005 Oct 7;280(40):33968-76
15994333
Nature. 1999 Sep 16;401(6750):272-6
10499584
Am J Respir Cell Mol Biol. 1991 Apr;4(4):295-300
1707633
Biochem J. 1986 Jan 15;233(2):309-19
3006665
Arthritis Rheum. 1999 Apr;42(4):609-21
10211874
Am J Physiol Cell Physiol. 2004 Apr;286(4):C923-30
14684387
Bone. 2002 Jan;30(1):32-9
11792562
J Leukoc Biol. 2002 Jul;72(1):222-32
12101284
J Leukoc Biol. 2006 Dec;80(6):1364-74
17020930
Nature. 2006 Aug 3;442(7102):527-32
16885977
Physiol Rev. 2002 Oct;82(4):1013-67
12270951
J Immunol. 2002 Jun 15;168(12):6436-45
12055263
Mol Biol Cell. 2005 Aug;16(8):3659-65
15944221
Curr Drug Targets Cardiovasc Haematol Disord. 2005 Feb;5(1):85-99
15720226
Biochem Biophys Res Commun. 2001 Dec 21;289(5):1275-81
11741333
EMBO J. 2007 Jun 20;26(12):2880-9
17476304
Nat Clin Pract Rheumatol. 2006 Aug;2(8):434-42
16932735
J Inflamm (Lond). 2007 Mar 16;4:5
17367517
Gynecol Oncol. 2007 Jul;106(1):233-43
17482244
Nat Cell Biol. 2002 May;4(5):E131-6
11988758
Purinergic Signal. 2005 Sep;1(3):205-9
18404505
Am J Respir Crit Care Med. 2005 Sep 15;172(6):671-8
15961692
FASEB J. 2003 Aug;17(11):1401-10
12890693
Clin Exp Immunol. 2006 Nov;146(2):253-61
17034577
Brain Res Mol Brain Res. 2004 Dec 20;132(2):146-54
15582154
J Neurosci. 2001 Jun 15;21(12):4134-42
11404398
J Leukoc Biol. 1998 Feb;63(2):139-52
9468273
J Biol Chem. 2004 May 7;279(19):20234-41
14993227
J Cell Physiol. 2007 Oct;213(1):36-44
17474086
J Biol Chem. 2001 Feb 9;276(6):3977-82
11092878
Bone. 2006 Aug;39(2):300-9
16616882
Mol Cell Biol. 2004 Apr;24(7):2820-30
15024071